| P50 | author | Françoise Brun-Vézinet | Q3086421 |
| | Geneviève Chêne | Q33101711 |
| | Sophie Matheron | Q37367444 |
| | Rodolphe Thiébaut | Q75483775 |
| | Florence Damond | Q87031003 |
| | Fabrice Bonnet | Q92078763 |
| | Estibaliz Lazaro | Q117255954 |
| | Julia Drylewicz | Q56809902 |
| | François Dabis | Q56850448 |
| P2093 | author name string | François Simon | |
| P2860 | cites work | Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 | Q22252321 |
| | Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal | Q22252852 |
| | Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? | Q25256872 |
| | Reduced rate of disease development after HIV-2 infection as compared to HIV-1 | Q28237927 |
| | Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV | Q28371880 |
| | Slower heterosexual spread of HIV-2 than HIV-1. | Q30419674 |
| | Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic | Q31095977 |
| | Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo | Q33793928 |
| | The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates | Q33884059 |
| | Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa | Q33958146 |
| | Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy | Q33966329 |
| | Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay | Q34041529 |
| | Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections | Q34199460 |
| | Natural killer cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall. | Q34434825 |
| | Highly active antiretroviral therapy and viral response in HIV type 2 infection | Q34548972 |
| | Mixed models for longitudinal left-censored repeated measures | Q35769431 |
| | Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection | Q35857567 |
| | Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France | Q36239954 |
| | Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection | Q36532659 |
| | Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? | Q36765448 |
| | Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission | Q37052996 |
| | Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load | Q58034113 |
| | Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates | Q59119688 |
| | HIV-1 and HIV-2 AIDS in African patients living in Paris | Q73429210 |
| | Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection | Q77296161 |
| | HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in the Eastern Region of Ghana, West Africa | Q78021137 |
| | Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia | Q46973654 |
| | Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients | Q46985383 |
| | Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort | Q47309372 |
| | Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection | Q47816992 |
| | Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. | Q51982441 |
| | Antiretroviral therapy for HIV-2 infected patients. | Q53995000 |
| | Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion | Q56530204 |
| | CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort | Q56762697 |
| | Monitoring the Dynamics of the HIV Epidemic Using Assays for Recent Infection and Serotyping among New HIV Diagnoses: Experience after 2 Years in France | Q56829540 |
| | In vitro replication capacity of HIV-2 variants from long-term aviremic individuals | Q56880140 |
| | Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. | Q37682830 |
| | T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection | Q38881288 |
| | Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire. | Q39142666 |
| | AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal | Q40613127 |
| | Differences in the interaction of HIV-1 and HIV-2 with CD4 | Q41757245 |
| | Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). | Q42912613 |
| | Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. | Q43823367 |
| | Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy | Q44031926 |
| | HIV-2 and T cell recognition | Q44220773 |
| | Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire | Q44622569 |
| | Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. | Q44622572 |
| | No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients | Q44743958 |
| | Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis | Q44811843 |
| | High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen | Q45032977 |
| | Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution | Q45745490 |
| | Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. | Q45747363 |
| | Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion | Q45868820 |
| | Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection. | Q46002704 |
| | Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. | Q46213922 |
| | Incidence of HIV-1 and HIV-2 infections in a rural community in southern Senegal | Q46282568 |
| | Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast | Q46363834 |
| | Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia | Q46593290 |
| | Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia | Q46603066 |
| | Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections | Q46605553 |
| | Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection | Q46808149 |
| | Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. | Q46874552 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 457-468 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France | |
| P478 | volume | 22 | |